June 3, 2008 - Breast-Specific Gamma Imaging (BSGI) is highly sensitive in detecting the presence of cancer and is as sensitive as MRI for most cancers, according to an article in the June issue of Radiology.

In the study, completed by The George Washington University Medical Center in Washington, D.C., 146 women underwent BSGI and breast biopsy. Study images were assigned scores, and scores were classified as positive or negative and compared with biopsy results. BSGI helped detect cancer in 96.4 percent of the noted malignant lesions; the positive predictive value was 68.8 percent, specificity of 59.5 percent and the negative predictive value for nonmalignant lesions was 94.3 percent. The smallest invasive cancer and DCIS detected were both 1 millimeter, and BSGI helped detect occult cancer not visualized at mammography or ultrasonography in six patients.

Mammography remains the imaging modality of choice for breast cancer screening. The overall sensitivity of mammography has been reported to be 78 to 85 percent; however, the sensitivity of mammography decreases to 42 to 68 percent in women with dense breasts. In addition, the false-positive rate of screening mammography is 15 to 30 percent, leading to many benign findings at biopsy. Limitations in the sensitivity and specificity of screening mammography led to the investigation of adjunct breast Imaging modalities; specifically BSGI, which provides physiological data not obtained with the anatomic Imaging techniques of mammography and ultrasound.

BSGI, molecular imaging of the breast utilizing a high-resolution, small-field-of-view gamma camera, is an increasingly utilized adjunct imaging modality for the diagnosis of breast cancer. Initial studies with this imaging technique report sensitivities similar to MRI with a higher specificity, which is the ability of a test to show when disease is not present.

For more information: www.gwumc.edu


Related Content

News | FDA

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
News | Mammography

April 16, 2024 — The Radiological Society of North America (RSNA) and GE HealthCare announced their collaboration to ...

Time April 16, 2024
arrow
News | Clinical Trials

April 16, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time April 16, 2024
arrow
News | Mammography

April 12, 2024 — Bayer and Hologic, Inc. announced a first-of-its-kind collaboration to deliver a coordinated solution ...

Time April 12, 2024
arrow
News | Mammography

April 12, 2024 — GE HealthCare, a leader in breast health technology and diagnostics, will feature its latest breast ...

Time April 12, 2024
arrow
News | Radiation Dose Management

April 11, 2024 — Prelude Corporation (PreludeDx), a leader in precision diagnostics for early-stage breast cancer ...

Time April 11, 2024
arrow
News | Mammography

April 11, 2024 — Volpara Health Technologies Ltd., a global leader in software for the early detection and prevention of ...

Time April 11, 2024
arrow
News | Society of Breast Imaging (SBI)

April 11, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered cancer detection solutions, announced today ...

Time April 11, 2024
arrow
News | Artificial Intelligence

April 9, 2024 —PreciseDx, a leading innovator in oncology diagnostics leveraging Artificial Intelligence (AI) for ...

Time April 09, 2024
arrow
News | Mammography

April 4, 2024 — Siemens Healthineers announces the Food and Drug Administration 510(k) clearance of the MAMMOMAT B ...

Time April 04, 2024
arrow
Subscribe Now